A Prospective, Randomized, Double-blind, Multicenter Study to Investigate the Safety and Duration of Effect of Different NT 201 Dose Groups Following the Treatment of Glabellar Frown Lines
Latest Information Update: 06 Oct 2023
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merz Aesthetics
Most Recent Events
- 07 Sep 2023 Safety end-points have been added.
- 03 Jun 2022 According to a Merz Aesthetics media release, full results from this trial will be presented at the 2022 International Master Course on Aging Science (IMCAS) World Congress.
- 20 Oct 2020 Status changed from active, no longer recruiting to completed.